Home > Insider Trading > Filing (0001209191-19-058110)

Filing Details

Accession Number:: 0001209191-19-058110
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-11-26 16:22:05
Reporting Period:: 2019-11-22

Accepted Time:: 2019-11-26 16:22:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1473930	Todd Foley	C/O Mpm Asset Management 450 Kendall Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-11-22	101,511	$21.78	2,767,094	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-22	1,171	$22.04	2,765,923	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-25	71,023	$23.04	2,694,900	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-25	50,320	$23.34	2,644,580	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The shares were sold as follows: 97,715 by MPM BioVentures V, L.P. ("BV V") and 3,796 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.025 to $22.00. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,663,617 by BV V and 103,477 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Shares were sold as follows: 1,127 by BV V and 44 by AM BV5.
Shares are held as follows: 2,662,490 by BV V and 103,433 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Shares were sold as follows: 68,367 by BV V and 2,656 by AM BV5.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.29 to $23.28. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,594,123 by BV V and 100,777 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Shares were sold as follows: 48,438 by BV V and 1,882 by AM BV5.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.29 to $23.39. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,545,685 by BV V and 98,895 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.